Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Kymera Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$287.57M. For fiscal 2025 it was -$232.89M. The highest annual figure on record is $88.13M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$232.89M | – |
| FY2024 | Dec 31, 2024 | -$194.50M | – |
| FY2023 | Dec 31, 2023 | -$102.83M | – |
| FY2022 | Dec 31, 2022 | -$153.09M | – |
| FY2021 | Dec 31, 2021 | -$128.95M | -246.3% |
| FY2020 | Dec 31, 2020 | $88.13M | +392.2% |
| FY2019 | Dec 31, 2019 | $17.91M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$77.91M | – |
| Q2 FY2026 | Jun 30, 2026 | -$54.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$88.84M | – |
| Q4 FY2025 | Dec 31, 2025 | -$66.75M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$59.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$79.15M | – |
| Q4 FY2024 | Dec 31, 2024 | -$61.78M | -868.0% |
| Q3 FY2024 | Sep 30, 2024 | -$50.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.94M | – |
| Q1 FY2024 | Mar 31, 2024 | -$39.59M | – |
| Q4 FY2023 | Dec 31, 2023 | $8.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.27M | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$40.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$38.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$37.26M | -128.3% |
| Q2 FY2021 | Jun 30, 2021 | -$30.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.07M | – |
| Q3 FY2020 | Sep 30, 2020 | $131.67M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.41M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.80M | – |
See a number that looks wrong?